Diabetes Pro Quarterly - Summer 2019 - 4

CLINICAL NEWS

American Diabetes Association Journals Lead in Performance Rankings
Diabetes Care and Diabetes, the
peer-reviewed research publications of the American Diabetes
Association (ADA), remain the
most influential journals devoted
exclusively to diabetes research and
treatment.
Based on Clarivate Analytics' recently released 2018 Journal
Citation Reports, Diabetes Care and
Diabetes lead the way among publications devoted to original diabetes
research. According to Eigenfactor,
a measure of a journal's total importance to the scientific community,
Diabetes Care and Diabetes are
the top two journals devoted to
diabetes research and rank second
and fourth among the 145 journals
indexed in the broader field of
endocrinology and metabolism.
Eigenfactor is calculated according
to the number of articles a journal publishes and the number of
citations it receives, with citations from high-impact journals
weighted more heavily in the calculation.
Diabetes Care and Diabetes are also among the top endocrinology and metabolism publications according to Clarivate Analytics'
Impact Factor. The Impact Factor for Diabetes Care increased

from 13.397 in 2017 to 15.270 in 2018-the highest Impact
Factor ever achieved by an ADA journal. Diabetes, ADA's flagship research publication, achieved an impressive 2018 Impact
Factor of 7.199.
In addition, BMJ Open Diabetes Research & Care, the BMJ
open-access journal published in partnership with the ADA,
received its first Impact Factor in 2018, reporting an impressive
first-year mark of 5.067, which ranks 25th of the 145 journals
indexed in the field of endocrinology and metabolism.
Impact Factor is a measure of how often work published in a
peer-reviewed journal is cited in other publications in a given
year. The statistic is considered to be a measure of a journal's
prestige and influence.
Diabetes Care and Diabetes also performed impressively according to the Article Influence Score, a measure of a journal's prominence based on per-article citations; Immediacy Index, a
measure of how quickly articles are cited; and Cited Half-Life,
the average age of cited articles.
Diabetes Care and Diabetes are two of the most highly cited publications in the field of endocrinology and metabolism. Combined,
the journals were cited more than 124,000 times in 2018.
To subscribe to or learn more about the ADA's journals, please
visit diabetesjournals.org. A subscription to Diabetes Care or
Diabetes is also included with ADA's Medicine & Science professional membership.
For further information about Impact Factor, Eigenfactor, and
other metrics, please visit wokinfo.com/essays.

Important Updates Made to the 2019 Standards of Medical Care in Diabetes
In July, the American Diabetes Association (ADA) issued
important updates to the Standards of Medical Care in
Diabetes-2019. In annotations made through its online "Living
Standards of Care" process, the association added new metrics
for continuous glucose monitoring (CGM) use and new medication options and recommendations for youth and adults with
type 2 diabetes. The updates were informed by recently published
research and crafted and approved by the ADA's Professional
Practice Committee, which is responsible for producing the
annual Standards. Updates to Section 10, Cardiovascular Disease
and Risk Management, were also reviewed and approved by the
American College of Cardiology, which endorses this section.
The July Living Standards update added information to the
following sections:
* Sections 6 (Glycemic Targets) and 7 (Diabetes Technology)
were revised to incorporate new CGM time-in-range goals
from an international consensus report. A table was added to
help standardize CGM metrics for clinical care, and an example of an ambulatory glucose profile was added to encourage
consistency in CGM data report interpretation.
4

* Sections 9 (Pharmacological Approaches to Glycemic
Treatment) and 10 (Cardiovascular Disease and Risk
Management) were updated to reflect the results of the
REWIND (Researching Cardiovascular Events With a Weekly
Incretin in Diabetes) trial, which found that dulaglutide
reduced the risk for nonfatal myocardial infarction, nonfatal
stroke, and cardiovascular death in adults with type 2 diabetes
with and without established cardiovascular disease.
* Revisions to sections 9 (Pharmacological Approaches to
Glycemic Treatment) and 13 (Children and Adolescents) were
made in response to the U.S. Food and Drug Administration's
approval of injectable liraglutide in pediatric patients with
type 2 diabetes who are ≥10 years of age and the publication
of a recent paper by Tamborlane et al., titled "Liraglutide in
Children and Adolescents with Type 2 Diabetes," which examined the drug's effects on youth. This is the first noninsulin
medication approved for the treatment of type 2 diabetes in
the pediatric population since 2000.
The complete Standards, an abridged version for primary care
providers, and other clinical resources can be accessed at professional.diabetes.org/standards.

http://www.diabetesjournals.org http://www.wokinfo.com/essays http://professional.diabetes.org/standards http://professional.diabetes.org/standards

Diabetes Pro Quarterly - Summer 2019

Table of Contents for the Digital Edition of Diabetes Pro Quarterly - Summer 2019